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INTRODUCTION
• Patients receiving oral anticoagulant
therapy who undergo minor oral surgical
procedures may have prolonged and
excessive hemorrhage.
• Temporarily withholding or decreasing the
dosage of the anticoagulant exposes the
patients to the risk of venous
thromboembolism and potential systemic
emboli from a cardiac source.
• Various protocols have been suggested for
treating these patients, including
substituting heparin for warfarin, decreasing
the level of anticoagulation preoperatively,
temporarily stopping the warfarin, and not
altering the anticoagulant regimen at all.
• There remains, however, no standard
therapeutic approach, and currently it
appears that each patient's treatment plan
is individually tailored by his or her
attending specialist.
INTRODUCTION
• In recent years, continuation of
anticoagulant therapy in oral surgical
procedures has gained more attention in
the international literature, emphasizing
the role of local hemostasis.
• There remains, however, a lack in
consensus of treatment methods to secure
this local hemostasis.
• Hemostasis in the oral cavity is dependent
on the dynamic balance between fibrin
formation and resolution and is influenced
by the external environment, which
contains both plasminogen and
plasminogen activators.
ANTIFIBRINOLYTIC AMINO 
ACIDS
• Two synthetic derivatives of the amino acid
lysine, 6-aminohexanoic acid
(aminocaproic acid) and 4-
(aminomethyl)cyclohexanecarboxylic acid
(tranexamic acid), have antifibrinolytic
activity in humans.
• Both drugs bind reversibly to plasminogen
and thereby block the binding of
plasminogen to fibrin and its activation and
transformation to plasmin.
activation of fibrinolysis inhibition of fibrinolysis
• Aminocaproic acid and tranexamic acid (which is
about 10 times more potent than aminocaproic
acid and has a longer half-life) are effective even
when bleeding is not associated with laboratory
signs of excessive fibrinolysis.
• Since both drugs enter the extravascular space and
accumulate in tissues,the basis for their efficacy is
thought to be the inhibition of tissue fibrinolysis and
the consequent stabilization of clots.
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ORAL BLEEDING IN CONGENITAL
AND ACQUIRED COAGULATION
DISORDERS
• Antifibrinolytic drugs are useful for the
control of bleeding after dental extractions
in patients with hemophilia, because the
oral mucosa and saliva are rich in
plasminogen activators.
• In two small clinical trials, aminocaproic
acid or tranexamic acid reduced recurrent
bleeding and the amount of clotting-
factor– replacement therapy needed.
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WHAT IS TRANEXAMIC
ACID? 
• Tranexamic acid is an antifibrinolytic agent
that inhibits the breakdown of fibrin clots. Its
primary action is to block the binding of
plasminogen and plasmin to fibrin therefore
preventing fibrinolysis.
• It has been used in anticoagulated dental
patients as a local haemostatic agent in
the form of a mouthwash.
TRANSAMIN ® - Tranexamic Acid 
-
5% tranexamic acid antifibrinolitic mouthwash rinise
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LOCAL HAEMOSTIC AGENTS
WHAT IS THE EVIDENCE OF
BENEFIT FOR TRANEXAMIC
ACID MOUTHWASH? 
• When used alone with no local
haemostatic dressing, tranexamic acid
mouthwash reduces postoperative
bleeding compared to placebo
mouthwash.
• When used in combination with local
haemostatic measures and suturing,
tranexamic acid mouthwash provides little
additional reduction in postoperative
bleeding.
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• The aim of the study was to
evaluate the mouthwash
solution (tranexamic acid) as a
local haemostatic modality
after oral surgery interventions.
MATERIALS AND METHODS
• To realize the aim 100 individuals who
received oral anticoagulants were
included.
• Oral surgery interventions were performed
with a reduction in the level of
anticoagulant therapy in the first group.
• Oral surgery interventions were realized in
the second group with no change in the
level of anticoagulant therapy and with
usage the tranexamic acid.
MATERIALS AND METHODS
• After the interventions the surgical field was
irrigated with a 5% solution of tranexamic
acid in the treatment group whose oral
anticoagulants had not been discontinued
(second group) and with a placebo
solution in the examined for whom the
anticoagulant therapy was reduced (first
group).
• Patients were instructed to rinse their
mouths with 10 ml of the assigned solution.
TABLE 1. PATIENTS THERAPEUTICALLY
ANTICOAGULATED WITH WARFARIN 
UNDERGOING
DENTAL EXTRACTIONS 
(N = 100 PATIENTS) Group A (55)  Group B (45) Total
• Gender
Male 26 25 52
Female 20 2 8 48
• Age range (yr) 24-85        40-83
• No. of extractions
Mandible                       46               32 78
Maxilla 25               49                             74
RESULTS
TABLE 2. PATIENTS THERAPEUTICALLY
ANTICOAGULATED WITH WARFARIN 
UNDERGOING
DENTAL EXTRACTIONS 
(N = 100 PATIENTS) Group A  Group B Total
• INR
Mean 3.0 3.1
Range 2.3-4.0                2.1-4.0
• Postoperative bleed (n)*
Mandible               0                       0                                 0
Maxilla                   0 2                                 2
• INR mean for
postoperative bleed 6.7 (range, 5.9-7.6)
RESULTS
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 The evidence from clinical trials and
focused reviews supports continuing oral
anticoagulation for patients needing
dentoalveolar surgery.
 As long as the INR is within the therapeutic
range and local hemostatic measures are
taken following the surgery, these patients will
have little chance of developing uncontrolled
bleeding following the surgery.
CONCLUSION
 Local hemostasis will control the bleeding in
the few patients who develop postsurgical
bleeding.
 The risk of uncontrolled life threatening
bleeding following dentoalveolar surgery is so
low that it is not necessary to stop
anticoagulation even for a short interval and
risk thromboembolism in patients on oral
anticoagulants.
CONCLUSION
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